Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenues:
Grant	$ 1,530	$ 488	$ 452
Sales and services	3,060	3,337	8
Total revenues	4,590	3,825	460
Operating costs and expenses:
Costs of revenues	1,950	2,043	4
Research and development	31,343	23,983	9,017
Acquired in-process research and development	24,013	209	5,986
General and administrative	20,132	9,987	6,317
Intangible amortization	1,157	2,345	804
Total costs and operating expenses	78,595	38,567	22,128
Loss from operations	(74,005)	(34,742)	(21,668)
Gain on sale of IgDraSol, net	69,274	0	0
Loss on derivative liability	(3,360)	0	0
Loss on equity investments	(4,041)	0	0
Interest expense	(1,652)	(1,629)	(253)
Interest income	24	12	10
Income (loss) before income tax expense	(13,760)	(36,359)	(21,911)
Income tax expense (benefit)	36,314	(1,702)	0
Net loss	(50,074)	(34,657)	(21,911)
Net loss attributable to noncontrolling interests	(4,263)	0	0
Net loss attributable to Sorrento	$ (45,811)	$ (34,657)	$ (21,911)
Net loss per share - basic and diluted per share attributable to Sorrento	$ (1.24)	$ (1.30)	$ (1.46)
Weighted-average shares used during period - basic and diluted per share attributable to Sorrento	36,909	26,679	15,046